Overview

A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
ABT-263 as single agent in women with platinum resistant/refractory recurrent ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Centre Francois Baclesse
Collaborators:
ARCAGY/ GINECO GROUP
French Cancer Research Hospital Program
Treatments:
Navitoclax